Aspira Women’s Health (NASDAQ:AWH) Stock Rating Upgraded by StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

Separately, Alliance Global Partners dropped their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Up 5.9 %

Shares of NASDAQ:AWH opened at $1.07 on Tuesday. The company has a market cap of $17.18 million, a price-to-earnings ratio of -0.74 and a beta of 1.54. The business has a 50 day moving average price of $1.34 and a 200 day moving average price of $2.65. Aspira Women’s Health has a twelve month low of $0.86 and a twelve month high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same period in the prior year, the company posted ($0.28) earnings per share. Analysts anticipate that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 179,371 shares of the company’s stock after acquiring an additional 53,997 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.73% of Aspira Women’s Health worth $732,000 as of its most recent filing with the SEC. 12.19% of the stock is owned by institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.